TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. Its lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. The Company's other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. 
San Diego, US
Size (employees)
26 (est)+19%
TRACON Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

Key People at TRACON Pharmaceuticals

Charles P. Theuer

Charles P. Theuer

President and CEO

TRACON Pharmaceuticals Office Locations

TRACON Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
4350 La Jolla Village Dr

TRACON Pharmaceuticals Data and Metrics

TRACON Pharmaceuticals Financial Metrics

$, USD

Net income (FY, 2016)

(27 m)

EBIT (FY, 2016)

(26 m)

Market capitalization (23-Jun-2017)

36.5 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

35.7 m
TRACON Pharmaceuticals's current market capitalization is $36.5 m.
$, USDFY, 2015FY, 2016

R&D expense

25.7 m21.6 m

General and administrative expense

5.7 m7.9 m

Operating expense total

31.4 m29.4 m


(23.5 m)(26 m)

Interest expense

(923 k)(1.1 m)

Net Income

(24.4 m)(27 m)
$, USDFY, 2015FY, 2016


41.4 m35.7 m

Accounts Receivable

9.4 m


8 m

Current Assets

53.3 m45.6 m


173 k82 k

Total Assets

53.5 m45.7 m

Accounts Payable

8.3 m6.2 m

Current Liabilities

14.2 m10.2 m

Additional Paid-in Capital

89.6 m113.9 m

Retained Earnings

(58.6 m)(85.6 m)

Total Equity

31 m28.3 m

Financial Leverage

1.7 x1.6 x
$, USDFY, 2015FY, 2016

Net Income

(24.4 m)(27 m)

Depreciation and Amortization

94 k

Accounts Payable

(2.2 m)

Cash From Operating Activities

(27.2 m)

Purchases of PP&E

(3 k)

Cash From Investing Activities

2.1 m

Long-term Borrowings

(2 m)

Cash From Financing Activities

19.4 m

Interest Paid

622 k
Y, 2016

Financial Leverage

1.6 x

TRACON Pharmaceuticals Market Value History

TRACON Pharmaceuticals Company Life and Culture

You may also be interested in